The present invention relates IL-17RE antagonists, such as soluble
receptors and anti-IL-17RE antibodies, that are useful in blocking,
inhibiting, reducing, antagonizing or neutralizing the activity of
IL-17C. IL-17C is a cytokine that is involved in inflammatory processes
and human disease. IL-17RE is a receptor for IL-17C. The present
invention includes soluble IL-17RE, anti-IL-17RE antibodies and binding
partners, as well as methods for antagonizing IL-17C using such soluble
receptors, antibodies and binding partners.